Literature DB >> 31605753

Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.

Ryan C Eid1, Eden Wudneh2, Soombal Zahid3, Katherine Cahill4, Elina Jerschow5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31605753      PMCID： PMC7114888          DOI： 10.1016/j.anai.2019.09.023

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  9 in total

1.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

Review 2.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

3.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  IL-5 synthesis is upregulated in human nasal polyp tissue.

Authors:  C Bachert; M Wagenmann; U Hauser; C Rudack
Journal:  J Allergy Clin Immunol       Date:  1997-06       Impact factor: 10.793

5.  A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.

Authors:  Katherine L Tuttle; Kathleen M Buchheit; Tanya M Laidlaw; Katherine N Cahill
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-06

6.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

7.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

8.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4.

Authors:  S E Dahlén; G Hansson; P Hedqvist; T Björck; E Granström; B Dahlén
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

9.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321
  9 in total
  2 in total

Review 1.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

Review 2.  Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

Authors:  Ryan Eid; Carol H Yan; Whitney Stevens; Taylor A Doherty; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2021-08       Impact factor: 14.290
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.